Description / Application
Seliciclib is 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors. It has a role as an antiviral drug and an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor.
Identities
| Alternative Name | Seliciclib; CYC202; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol |
|---|---|
| Molecular Formula | C19H26N6O |
| Molecular Weight | 354.4 |
| MFCD | MFCD02266401 |
Safety
| Pictograms |
|
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315;H319;H335 |
| Precautionary Statements | P261;P264;P271;P280;P302+P352;P304+P340;P305+P351+P338;P312;P321;P332+P313;P337+P313;P362;P403+P233;P405;P501 |